Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China's CBMG Signs Up GE China to Develop Immunotherapy/Stem Cell Processes

publication date: Apr 11, 2017
Cellular Biomedicine formed a strategic collaboration with GE Healthcare Life Sciences China to co-develop an automated autologous cell preparation system for immunotherapy/stem cell manufacturing. To develop the processes, the two companies will build a joint laboratory inside CBMG’s new Zhangjiang GMP facility in Shanghai. CBMG developed its own progenitor and dendritic cell therapies for cancer and osteoarthritis. Two years ago, it acquired CAR-T cancer immunotherapy technology from the Chinese PLA 301 Hospital of Beijing. More details...

Stock Symbol: (NSDQ: CBMG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital